Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endophthalmitis | 3 | 2010 | 11 | 0.740 |
Why?
|
| Acanthamoeba | 1 | 2010 | 3 | 0.340 |
Why?
|
| Amebiasis | 1 | 2010 | 3 | 0.340 |
Why?
|
| Acanthamoeba Keratitis | 1 | 2010 | 3 | 0.340 |
Why?
|
| Eye Infections, Parasitic | 1 | 2010 | 4 | 0.340 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2010 | 9 | 0.340 |
Why?
|
| Staphylococcus epidermidis | 1 | 2009 | 4 | 0.330 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2009 | 6 | 0.330 |
Why?
|
| Eye Infections, Bacterial | 1 | 2009 | 9 | 0.330 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 162 | 0.280 |
Why?
|
| Choroid Neoplasms | 1 | 2003 | 1 | 0.220 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 50 | 0.210 |
Why?
|
| Postoperative Complications | 1 | 2009 | 916 | 0.210 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 137 | 0.200 |
Why?
|
| Vitrectomy | 2 | 2014 | 10 | 0.200 |
Why?
|
| Vitreous Body | 2 | 2010 | 8 | 0.170 |
Why?
|
| Vitreous Hemorrhage | 1 | 2014 | 3 | 0.110 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 5 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 15 | 0.110 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 23 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 85 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2013 | 5 | 0.110 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 6 | 0.100 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2010 | 3 | 0.090 |
Why?
|
| Eye Enucleation | 1 | 2010 | 3 | 0.090 |
Why?
|
| Antiprotozoal Agents | 1 | 2010 | 8 | 0.090 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 88 | 0.080 |
Why?
|
| Middle Aged | 5 | 2014 | 8923 | 0.080 |
Why?
|
| Prednisolone | 1 | 2009 | 8 | 0.080 |
Why?
|
| Lenses, Intraocular | 1 | 2009 | 4 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2009 | 14 | 0.080 |
Why?
|
| Visual Acuity | 1 | 2009 | 41 | 0.080 |
Why?
|
| Microsurgery | 1 | 2009 | 42 | 0.080 |
Why?
|
| Vancomycin | 1 | 2009 | 52 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 161 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2009 | 68 | 0.080 |
Why?
|
| Ganciclovir | 1 | 2006 | 8 | 0.070 |
Why?
|
| Drug Implants | 1 | 2006 | 9 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 370 | 0.070 |
Why?
|
| Humans | 6 | 2014 | 27072 | 0.070 |
Why?
|
| Foreign-Body Migration | 1 | 2006 | 19 | 0.070 |
Why?
|
| Female | 4 | 2014 | 15212 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2006 | 50 | 0.060 |
Why?
|
| Adult | 3 | 2014 | 7831 | 0.060 |
Why?
|
| Fluorescein Angiography | 1 | 2003 | 3 | 0.060 |
Why?
|
| Leucovorin | 1 | 2003 | 8 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2003 | 46 | 0.050 |
Why?
|
| Carboplatin | 1 | 2003 | 26 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2003 | 54 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 300 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 245 | 0.050 |
Why?
|
| Aged | 3 | 2014 | 8997 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2014 | 21 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2014 | 11 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2014 | 3538 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 310 | 0.030 |
Why?
|
| Male | 2 | 2014 | 14772 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2013 | 31 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 99 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 363 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 1792 | 0.020 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2006 | 2 | 0.020 |
Why?
|
| Device Removal | 1 | 2006 | 85 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 3485 | 0.010 |
Why?
|